<DOC>
	<DOCNO>NCT01354652</DOCNO>
	<brief_summary>The purpose study investigate whether entecavir treatment increase incidence lactic acidosis compare another nucleoside/nucleotide reverse transcriptase inhibitor ( NRTI ) , lamivudine , and/or NRTI treatment , patient cirrhosis hepatic failure whose Model End stage Liver Disease ( MELD ) score 18 .</brief_summary>
	<brief_title>Lactic Acidosis During Entecavir ( ETV ) Treatment</brief_title>
	<detailed_description>Chronic hepatitis B virus ( HBV ) infection major cause hepatic failure worldwide . Although clinical course HBV infection varies widely , prognosis decompensated liver cirrhosis quite poor 5-year survival rate estimate 14-35 % without treatment . While ultimate treatment decompensated cirrhosis orthotopic liver transplantation ( OLT ) , several study suggest anti-viral therapy also improve clinical outcome group patient . Entecavir ( ETV ) potent cyclopentyl guanosine nucleoside inhibitor HBV polymerase . It high anti-viral potency low resistance rate compare lamivudine ( LAM ) , telbivudine adefovir , use nucleoside/nucleotide-na√Øve patient . ETV show effective patient hepatitis B envelope antigen ( HBeAg ) -positive HBeAg-negative chronic hepatitis B , compensate liver disease . As patient decompensated cirrhosis , investigator recently report ETV induce virological response also improve underlie hepatic function , thereby reduce need OLT . The cumulative OLT-free survival 1 year 2 year 87.1 % 83 % , respectively ETV treatment . Despite dramatic benefit ETV treatment , recent study report ETV may induce lactic acidosis patient severe hepatic and/or renal function impairment . Lange et al . report 5 16 patient severely impaired liver function develop lactic acidosis ETV treatment . Of note , five patient develop lactic acidosis MELD score 20 , increase serum lactate concentration observe 11 patient whose MELD score 18 . The Child-Pugh score correlate insufficiently risk lactic acidosis . This result contradictory previous study , since investigator analyze incidence lactic acidosis MELD score study patient relatively low ( mean value : 11.5 ) study . Lactic acidosis report occasionally association nucleoside/nucleotide reverse transcriptase inhibitor ( NRTIs ) . NRTIs induce lactic acidosis via interaction mitochondrial DNA polymerase . Until , report case human immunodeficiency virus ( HIV ) -infected subject treat several nucleoside inhibitor HIV reverse transcriptase . Risk factor include didanosine , stavudine , combination two , female gender , age 40 year , low CD4 count , short duration therapy ( le 12 month ) . As non-HIV-infected case , one case report fatal lactic acidosis combination therapy adefovir entecavir prior report Lange et al . Interestingly , vitro inhibition mitochondrial DNA polymerase show lamivudine , adefovir tenofovir , entecavir . Lactate level blood result balance production clearance . In normal physiologic condition , lactate produce primarily skeletal muscle , skin , brain , intestine red blood cell . In severe illness , produce many tissue include lung , leukocytes , liver , intestine . Lactate clearance occur principally liver ( 60 % ) , kidney ( 30 % ) , heart skeletal muscle . For reason , though lactic acidosis typically present shock state oxygen delivery insufficient meet cellular demand , elevate blood level also result chronic liver disease renal impairment . In addition , many condition report association lactic acidosis even without ongoing evidence hypoxia ischemia . Examples malignancy-related metabolic shift , systemic inflammatory response , hepatic failure , various drug include acetaminophen , NRTIs , metformin , propofol , thiamine deficiency , total parenteral nutrition , even lactulose . Therefore , critically ill patient cirrhosis hepatic failure , lactic acidosis result various cause combination , addition NRTIs . First , liver failure per se associate decreased lactate clearance , aggravate sepsis renal failure . The liver also source lactate production many medication NRTIs precipitate lactic acidosis . For reason , still conclusive whether ETV treatment direct cause lactic acidosis critically ill patient cirrhosis hepatic failure , since control group study Lange et al . A similar scenario observe study perform HIV-infected patient , mitochondrial-to-nuclear DNA ratio compare among non-HIV-infected control , HIV-infected individual NRTIs , HIV-infected individual NRTIs . In study , HIV alone affect mitochondrial-to-nuclear DNA ratio , therefore result lactic acidosis . Recently , Wong et al . report safety efficacy ETV patient severe acute exacerbation compare LAM . In study , ETV treatment associate increase short-term mortality patient severe acute exacerbation chronic hepatitis B achieve well virological response long run . Wong et al . assume cause increase short-term mortality ETV-treated patient due strong immune response also lactic acidosis . As , suggest LAM may initiate first routine switching ETV liver function improve adoption roadmap concept reasonable treatment strategy . However , drug resistance problem long term increase resistance mutation lamivudine entecavir late patient history exposure lamivudine entecavir treatment past treated lamivudine . Thus , aim study investigate whether ETV treatment increase incidence lactic acidosis compare another NRTI , lamivudine , and/or NRTI treatment , patient cirrhosis hepatic failure whose MELD score 18 .</detailed_description>
	<mesh_term>Acidosis</mesh_term>
	<mesh_term>Acidosis , Lactic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1. ETV LAM group Inclusion criterion : 18 18 year , less 65 year HBVrelated liver cirrhosis acuteonchronic liver failure Prior documentation chronic HBV infection least 6 month randomization MELD score 18 18 Venous blood lactate level 2 less 2 mmol/L Exclusion criterion : Age 65 old , young 18 Patients acute hepatitis B include acute liver failure Acuteonchronic liver failure precipitate acute hepatitis A acetaminophen intoxication MELD score less 18 entecavir , lamivudine , telbivudine , clevudine , adefovir tenofovir treatment continue long 3 month entry . Evidence genotypic virological resistance lamivudine , clevudine , telbivudine , adefovir Patients elevate venous blood lactate level 2 mmol/L Recent episodes active infection , hypotension ( systolic blood pressure le 90 mmHg ) , gastrointestinal active bleeding within 2 week entry Any alcohol intake within 2 week entry Recent use acetaminophen , epinephrine , metformin , iron , isoniazid , propofol , salicylate , sulfasalazine , valproic acid within 2 week entry . Use lactulose permit . Presence hepatocellular carcinoma . Patients hepatocellular carcinoma meeting Milan criterion permit . Any cancer hepatocellular carcinoma except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis &amp; T1 ) . Any cancer curatively treat least 3 year prior entry permit . Patients HIV infection Female patient pregnancy 2. NRTI group Inclusion criterion : Age 65 old , young 18 Liver cirrhosis acuteonchronic liver failure relate HBV MELD score 18 18 Venous blood lactate level 2 less 2 mmol/L Exclusion criterion : Age 65 old , young 18 Patients positive HBsAg IgM antiHBc Acuteonchronic liver failure precipitate acute hepatitis A acetaminophen intoxication MELD score less 18 Patients elevate venous blood lactate level 2 mmol/L Recent episodes active infection , hypotension ( systolic blood pressure le 90 mmHg ) , gastrointestinal active bleeding within 2 week entry Any alcohol intake within 2 week entry Recent use acetaminophen , epinephrine , metformin , iron , isoniazid , propofol , salicylate , sulfasalazine , valproic acid within 2 week entry . Use lactulose permit . Presence hepatocellular carcinoma . Patients hepatocellular carcinoma within Milan criterion permit . Any cancer hepatocellular carcinoma except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis &amp; T1 ) . Any cancer curatively treat least 3 year prior entry permit . Patients HIV infection Female patient pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>lactic acidosis</keyword>
	<keyword>entecavir</keyword>
	<keyword>lamivudine</keyword>
</DOC>